Both Novo Nord's Dual GIP/GLP-1 and Semaglutide are new medications designed for managing hyperglycemia and supporting weight reduction . However, they function through varied processes . copyright is a GLP-1 receptor area stimulator, while Retatrutide acts as a dual GIP and GLP-1 agonist , conceivably offering a larger impact on combined glucose c